

Pharmaceutical Management Agency

# Section H Update for Hospital Pharmaceuticals

Effective 1 April 2019



# Contents

Summary of decisions effective 1 April 2019.....	3
Section H changes to Part II .....	5
Index.....	9

## Summary of decisions

EFFECTIVE 1 APRIL 2019

- Amiodarone hydrochloride (Lodi) inj 50 mg per ml, 3 ml ampoule – HSS suspended
- Amiodarone hydrochloride (Cordarone-X) inj 50 mg per ml, 3 ml ampoule – new listing
- Atazanavir sulphate (Teva) cap 150 mg and 200 mg – new listing and addition of HSS
- Atazanavir sulphate (Reyataz) cap 150 mg and 200 mg – to be delisted 1 June 2019
- Calcium carbonate (Calsource) tab eff 1.75 g (1 g elemental) – delisting delayed
- Carboplatin (Carboplatin Ebewe) inj 10 mg per ml, 45 ml vial – new listing and addition of HSS
- Carboplatin (DBL Carboplatin) inj 10 mg per ml, 45 ml vial – to be delisted 1 June 2019
- Efavirenz with emtricitabine and tenofovir disoproxil (Mylan) tab 600 mg with emtricitabine 200 mg and tenofovir disoproxil 245 mg (300 mg as a maleate) – new listing and addition of HSS
- Efavirenz with emtricitabine and tenofovir disoproxil (Atripla) tab 600 mg with emtricitabine 200 mg and tenofovir disoproxil 245 mg (300 mg as a fumarate) – amended chemical and presentation name and to be delisted 1 June 2019
- Emtricitabine with tenofovir disoproxil (Teva) tab 200 mg with tenofovir disoproxil 245 mg (300.6 mg as a succinate) – new listing and addition of HSS
- Emtricitabine with tenofovir disoproxil (Truvada) tab 200 mg with tenofovir disoproxil 245 mg (300 mg as a fumarate) – amended chemical and presentation name and to be delisted from 1 June 2019
- Etoposide (Vepesid) cap 50 mg and 100 mg – addition of HSS
- Glycerin with sodium saccharin (Ora-Sweet SF) suspension – price decrease and addition of HSS
- Glycerin with sucrose (Ora-Sweet) suspension – price decrease and addition of HSS
- Hydrocortisone butyrate (Locoid Lipocream) crm 0.1% – price increase
- Imipenem with cilastatin (Imipenem+Cilastin RBX) inj 500 mg with 500 mg cilastatin vial – addition of HSS
- Influenza vaccine (Influvac Tetra) inj 60 mcg in 0.5 ml syringe (quadrivalent vaccine) – Pharmacode change and amended restriction
- Influenza vaccine (Fluarix Tetra) inj 60 mcg in 0.5 ml syringe (paediatric quadrivalent vaccine) – amended restriction

## Summary of decisions – effective 1 April 2019 (continued)

- Lidocaine [lignocaine] hydrochloride (Xylocaine) spray 10% – addition of HSS
- Lidocaine [lignocaine] hydrochloride (Lidocaine-Clarix) inj 1% and 2%, 20 ml vial – price decrease and addition of HSS
- Mercaptopurine (Puri-nethol) tab 50 mg – price decrease and addition of HSS
- Methyl hydroxybenzoate (Midwest) powder, 25 g – new listing and addition of HSS
- Methylcellulose (Midwest) powder, 100 g – new listing and addition of HSS
- Methylcellulose (Ora-Plus) suspension – price decrease and addition of HSS
- Methylcellulose with glycerin and sodium saccharin (Ora-Blend SF) suspension – price decrease and addition of HSS
- Methylcellulose with glycerin and sucrose (Ora-Blend) suspension – price decrease and addition of HSS
- Metoclopramide hydrochloride (Pfizer) inj 5 mg per ml, 5 ml ampoule – price increase
- Prilocaine hydrochloride (Citanest) inj 2%, 5 ml ampoule – to be delisted 1 October 2019

	Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

## Section H changes to Part II

Effective 1 April 2019

### ALIMENTARY TRACT AND METABOLISM

17	CALCIUM CARBONATE (delisting delayed) Tab eff 1.75 g (1 g elemental).....	2.07	10	Calsource
	Note – Calsource tab eff 1.75 g (1 g elemental) delisting delayed from 1 July 2019 to 1 September 2019.			

### CARDIOVASCULAR SYSTEM

39	AMIODARONE HYDROCHLORIDE (HSS suspended) Inj 50 mg per ml, 3 ml ampoule – 1% DV Jun-17 to <del>2019-31</del> <b>March 2019</b> .....	9.98	5	Lodi
39	AMIODARONE HYDROCHLORIDE (new listing) Inj 50 mg per ml, 3 ml ampoule .....	11.98	6	Cordarone-X

### DERMATOLOGICALS

54	HYDROCORTISONE BUTYRATE (↑ price) Crm 0.1%.....	3.42	30 g	Locoid Lipocream
----	--	------	------	------------------

### INFECTIONS

72	IMIPENEM WITH CILASTATIN (addition of HSS) → Inj 500 mg with 500 mg cilastatin vial – 1% DV Jul-19 to 2022 .....	60.00	1	<b>Imipenem + Cilastatin RBX</b>
86	EFAVIRENZ WITH EMTRICITABINE AND TENOFOVIR DISOPROXIL (new listing) → Tab 600 mg with emtricitabine 200 mg and tenofovir disoproxil 245 mg (300 mg as a maleate) – 1% DV Jun-19 to 2022 ..	106.88	30	<b>Mylan</b>
86	EFAVIRENZ WITH EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE (amended chemical and presentation name and delisting) → Tab 600 mg with emtricitabine 200 mg and tenofovir disoproxil <b>245 mg (300 mg as a fumarate)</b> .....	237.52	30	Atripla
	Note – Atripla to be delisted from 1 June 2019.			
87	ATAZANAVIR SULPHATE (brand change) → Cap 150 mg – 1% DV Jun-19 to 2022 .....	141.68	60	<b>Teva</b>
	→ Cap 200 mg – 1% DV Jun-19 to 2022 .....	188.91	60	<b>Teva</b>
	Note – Reyataz cap 150 mg and 200 mg to be delisted from 1 June 2019.			
90	EMTRICITABINE WITH TENOFOVIR DISOPROXIL (new listing) → Tab 200 mg with tenofovir disoproxil 245 mg (300.6 mg as a succinate) – 1% DV Jun-19 to 2022 .....	61.15	30	<b>Teva</b>

		Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	--	------------------------------------	-----	-------------------------------------

## Changes to Section H Part II – effective 1 April 2019 (continued)

90	EMTRICITABINE WITH TENOFOVIR DISOPROXIL FUMARATE (amended chemical and presentation name and delisting) → Tab 200 mg with tenofovir disoproxil <b>245 mg</b> (300 mg as a fumarate).....	190.02	30	Truvada
Note – Truvada to be delisted from 1 June 2019.				

## NERVOUS SYSTEM

109	LIDOCAINE [LIGNOCAINE] HYDROCHLORIDE (addition of HSS) Spray 10% – <b>1% DV Jul-19 to 2022</b> .....	75.00	50 ml	<b>Xylocaine</b>
109	LIDOCAINE [LIGNOCAINE] HYDROCHLORIDE (↓ price and addition of HSS) Inj 1%, 20 ml vial – <b>1% DV Jul-19 to 2022</b> ..... Inj 2%, 20 ml vial – <b>1% DV Jul-19 to 2022</b> .....	6.20 6.45	5 5	<b>Lidocaine-Claris</b> <b>Lidocaine-Claris</b>
109	PRILOCAINE HYDROCHLORIDE (delisting) Inj 2%, 5 ml ampoule.....	55.00	10	Citanest
Note – Citanest inj 2%, 5 ml ampoule to be delisted from 1 October 2019.				
119	METOCLOPRAMIDE HYDROCHLORIDE (↑ price) Inj 5 mg per ml, 2 ml ampoule.....	13.56	10	Pfizer

## ONCOLOGY AGENTS AND IMMUNOSUPPRESSANTS

133	MERCAPTOPYRINE (↓ price and addition of HSS) Tab 50 mg – <b>1% DV Jul-19 to 2022</b> .....	37.00	25	<b>Puri-nethol</b>
135	ETOPOSIDE (addition of HSS) Cap 50 mg – <b>1% DV Jul-19 to 2022</b> ..... Cap 100 mg – <b>1% DV Jul-19 to 2022</b> .....	340.73 340.73	20 10	<b>Vepesid</b> <b>Vepesid</b>
138	CARBOPLATIN (brand change) Inj 10 mg per ml, 45 ml vial – <b>1% DV Jun-19 to 2021</b> .....	45.20	1	<b>Carboplatin Ebewe</b>
Note – DBL Carboplatin inj 10 mg per ml, 45 ml vial to be delisted from 1 June 2019.				

## EXTEMPORANEOUSLY COMPOUNDED PREPARATIONS

212	GLYCERIN WITH SODIUM SACCHARIN (↓ price and addition of HSS) Suspension – <b>1% DV Jul-19 to 2022</b> .....	30.95	473 ml	<b>Ora-Sweet SF</b>
212	GLYCERIN WITH SUCROSE (↓ price and addition of HSS) Suspension – <b>1% DV Jul-19 to 2022</b> .....	30.95	473 ml	<b>Ora-Sweet</b>
212	METHYL HYDROXYBENZOATE (new listing) Powder – <b>1% DV Jul-19 to 2022</b> .....	8.98	25 g	<b>Midwest</b>
212	METHYLCELLULOSE (new listing) Powder – <b>1% DV Jul-19 to 2022</b> .....	36.95	100 g	<b>Midwest</b>

→ Restriction

(Brand) indicates a brand example only. It is not a contracted product.

		Price (ex man. Excl. GST) \$ Per	Brand or Generic Manufacturer
--	--	--	-------------------------------------

## Changes to Section H Part II – effective 1 April 2019 (continued)

212	METHYLCELLULOSE (↓ price and addition of HSS) Suspension – <b>1% DV Jul-19 to 2022</b> .....	30.95	473 ml	<b>Ora-Plus</b>
212	METHYLCELLULOSE WITH GLYCERIN AND SODIUM SACCHARIN (↓ price and addition of HSS) Suspension – <b>1% DV Jul-19 to 2022</b> .....	30.95	473 ml	<b>Ora-Blend SF</b>
212	METHYLCELLULOSE WITH GLYCERIN AND SUCROSE (↓ price and addition of HSS) Suspension – <b>1% DV Jul-19 to 2022</b> .....	30.95	473 ml	<b>Ora-Blend</b>

## VACCINES

235	INFLUENZA VACCINE (Pharmacode change) → Inj 60 mcg in 0.5 ml syringe (quadrivalent vaccine) .....	90.00	10	Influvac Tetra
Note – this is a new Pharmacode listing, 2558483. Pharmacode 2538466 to be delisted from 1 July 2019.				
235	INFLUENZA VACCINE (amended restriction – affected criteria only shown) → Inj 60 mcg in 0.5 ml syringe (paediatric quadrivalent vaccine) ..	9.00	1	Fluarix Tetra
Restricted				
Initiation – Other conditions for patients aged 6 months to 35 months				
Any of the following:				
1 Any of the following:				
1.1 Diabetes; or				
1.2 Chronic renal disease; or				
1.3 Any cancer, excluding basal and squamous skin cancers if not invasive; or				
1.4 Autoimmune disease; or				
1.5 Immune suppression or immune deficiency; or				
1.6 HIV; or				
1.7 Transplant recipient; or				
1.8 Neuromuscular and CNS diseases/ disorders; or				
1.9 Haemoglobinopathies; or				
1.10 Is a child on long term aspirin; or				
1.11 Has a cochlear implant; or				
1.12 Errors of metabolism at risk of major metabolic decompensation; or				
1.13 Pre and post splenectomy; or				
1.14 Down syndrome; or				
1.15 Child who has been hospitalised for respiratory illness or has a history of significant respiratory illness;				
or				
2 Child is living in the Seddon/Ward and rural Eastern Marlborough region (within the Nelson Marlborough District Health Board) and Kaikoura and Hurunui areas (within the Canterbury District Health Board)				
→ Inj 60 mcg in 0.5 ml syringe (quadrivalent vaccine) .....				
90.00				
10				
Influvac Tetra				
Initiation – Other conditions for patients 3 years and over				
Any of the following: <b>Either:</b>				
1 Any of the following:				
1.1 Diabetes; or				
1.2 chronic renal disease; or				
1.3 Any cancer, excluding basal and squamous skin cancers if not invasive; or				
1.4 Autoimmune disease; or				
1.5 Immune suppression or immune deficiency; or				
1.6 HIV; or				
1.7 Transplant recipient; or				
1.8 Neuromuscular and CNS diseases/ disorders; or				

continued...

Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
------------------------------------	-----	-------------------------------------

## Changes to Section H Part II – effective 1 April 2019 (continued)

*continued...*

- 1.9 Haemoglobinopathies; or
- 1.10 Is a child on long term aspirin; or
- 1.11 Has a cochlear implant; or
- 1.12 Errors of metabolism at risk of major metabolic decompensation; or
- 1.13 Pre and post splenectomy; or
- 1.14 Down syndrome; or
- 1.15 Is pregnant; or
- 1.16 Is a child aged four and under who has been hospitalised for respiratory illness or has a history of significant respiratory illness; or
- 2 Patients in a long-stay inpatient mental health care unit or who are compulsorily detained long-term in a forensic unit within a DHB hospital; or
- ~~3 People under 18 years of age living in the Seddon/Ward and rural Eastern Marlborough region (within the Nelson Marlborough District Health Board) and Kaikoura and Hurunui areas (within the Canterbury District Health Board)~~



# Index

## Pharmaceuticals and brands

<b>A</b>		
Amiodarone hydrochloride.....	5	
Atazanavir sulphate .....	5	
Atripla .....	5	
<b>C</b>		
Calcium carbonate .....	5	
Calsource .....	5	
Carboplatin .....	6	
Carboplatin Ebewe .....	6	
Citanest .....	6	
Cardarone-X .....	5	
<b>E</b>		
Efavirenz with emtricitabine and tenofovir disoproxil.....	5	
Efavirenz with emtricitabine and tenofovir disoproxil fumarate .....	5	
Emtricitabine with tenofovir disoproxil.....	5, 6	
Emtricitabine with tenofovir disoproxil fumarate ....	6	
Etoposide.....	6	
<b>F</b>		
Fluarix Tetra .....	7	
<b>G</b>		
Glycerin with sodium saccharin.....	6	
Glycerin with sucrose.....	6	
<b>H</b>		
Hydrocortisone butyrate .....	5	
<b>I</b>		
Imipenem + Cilastatin RBX.....	5	
Imipenem with cilastatin.....	5	
Influenza vaccine.....	7	
Influvac Tetra .....	7	
<b>L</b>		
Lidocaine-Claris .....	6	
Lidocaine [Lignocaine] hydrochloride .....	6	
Lignocaine .....	6	
Locoid Lipocream .....	5	
Lodi .....	5	
<b>M</b>		
Mercaptopurine.....	6	
Methylcellulose .....	6, 7	
Methylcellulose with glycerin and sodium saccharin.....	7	
Methylcellulose with glycerin and sucrose .....	7	
Methyl hydroxybenzoate .....	6	
Metoclopramide hydrochloride .....	6	
<b>O</b>		
Ora-Blend .....	7	
Ora-Blend SF.....	7	
Ora-Plus .....	7	
Ora-Sweet.....	6	
Ora-Sweet SF.....	6	
<b>P</b>		
Prilocaine hydrochloride .....	6	
Puri-nethol .....	6	
<b>T</b>		
Truvada .....	6	
<b>V</b>		
Vepesid.....	6	
<b>X</b>		
Xylocaine .....	6	



### **Pharmaceutical Management Agency**

Level 9, 40 Mercer Street, PO Box 10254, Wellington 6143, New Zealand

Phone: 64 4 460 4990

Fax: 64 4 460 4995

Website: [www.pharmac.govt.nz](http://www.pharmac.govt.nz)

Email: [enquiry@pharmac.govt.nz](mailto:enquiry@pharmac.govt.nz)

**ISSN 1179-3694 (Print)**

**ISSN 1179-3708 (Online)**

While care has been taken in compiling this Update, Pharmaceutical Management Agency takes no responsibility for any errors or omissions and shall not be liable to any person for any damages or loss arising out of reliance by that person for any purpose on any of the contents of this Update. Errors and omissions brought to the attention of Pharmaceutical Management Agency will be corrected if necessary by an erratum or otherwise in the next edition of the update.

If Undelivered, Return To: PO Box 10254, Wellington 6143, New Zealand